Old West Investment Management LLC Buys 9,995 Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

Old West Investment Management LLC grew its stake in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 17.7% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 66,452 shares of the biotechnology company’s stock after purchasing an additional 9,995 shares during the quarter. Old West Investment Management LLC’s holdings in Ironwood Pharmaceuticals were worth $433,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Vanguard Group Inc. grew its holdings in Ironwood Pharmaceuticals by 21.8% during the first quarter. Vanguard Group Inc. now owns 19,521,366 shares of the biotechnology company’s stock worth $170,031,000 after purchasing an additional 3,487,821 shares during the period. Renaissance Technologies LLC lifted its position in shares of Ironwood Pharmaceuticals by 20.7% in the second quarter. Renaissance Technologies LLC now owns 8,571,898 shares of the biotechnology company’s stock valued at $55,889,000 after buying an additional 1,472,097 shares during the last quarter. Armistice Capital LLC boosted its stake in shares of Ironwood Pharmaceuticals by 64.9% during the 4th quarter. Armistice Capital LLC now owns 5,700,000 shares of the biotechnology company’s stock worth $65,208,000 after acquiring an additional 2,244,000 shares during the period. Jacobs Levy Equity Management Inc. increased its holdings in shares of Ironwood Pharmaceuticals by 40.8% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 4,235,580 shares of the biotechnology company’s stock worth $36,892,000 after acquiring an additional 1,226,377 shares during the last quarter. Finally, Kynam Capital Management LP bought a new stake in Ironwood Pharmaceuticals in the 1st quarter valued at $14,154,000.

Insider Buying and Selling

In other Ironwood Pharmaceuticals news, insider Minardo John sold 9,910 shares of the firm’s stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $4.27, for a total value of $42,315.70. Following the transaction, the insider now directly owns 284,661 shares of the company’s stock, valued at approximately $1,215,502.47. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 12.90% of the stock is currently owned by company insiders.

Ironwood Pharmaceuticals Price Performance

Shares of NASDAQ IRWD opened at $4.47 on Tuesday. The stock has a market capitalization of $714.04 million, a PE ratio of -0.66 and a beta of 0.49. Ironwood Pharmaceuticals, Inc. has a fifty-two week low of $3.79 and a fifty-two week high of $15.70. The business has a fifty day moving average price of $5.50 and a two-hundred day moving average price of $6.73.

Analysts Set New Price Targets

IRWD has been the topic of several research reports. Leerink Partnrs upgraded shares of Ironwood Pharmaceuticals to a “hold” rating in a report on Monday, September 9th. StockNews.com raised shares of Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, July 16th. Capital One Financial downgraded shares of Ironwood Pharmaceuticals from an “overweight” rating to an “equal weight” rating and cut their price objective for the stock from $12.00 to $4.00 in a research report on Thursday, August 8th. Wells Fargo & Company decreased their target price on Ironwood Pharmaceuticals from $14.00 to $12.00 and set an “overweight” rating on the stock in a research report on Friday, August 9th. Finally, Craig Hallum dropped their price target on Ironwood Pharmaceuticals from $14.00 to $10.00 and set a “buy” rating for the company in a report on Friday, August 9th. Three research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, Ironwood Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $13.57.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.